27 April 2017
EMEA/252290/2017
EMEA/H/C/000775

Public statement

Imprida

Withdrawal of the marketing authorisation in the European Union

On 3 April 2017, the European Commission withdrew the marketing authorisation for Imprida (amlodipine / valsartan) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Novartis Europharm Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Imprida was granted marketing authorisation in the EU on 17 January 2007 for treatment of essential hypertension. It was then granted unlimited validity in 2011.

Imprida is a medicine that contains two active substances, amlodipine and valsartan. There are other medicinal products marketed in the EU that contain this combination of substances as well as products containing amlodipine or valsartan alone.

The European Public Assessment Report (EPAR) for Imprida will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact